BR9611035A - Uso de pelo menos um ligante que é selecionado entre um ligante agonista que é especifico para receptores do tipo rar-a e um ligante antagonista que é especifico para receptores do tipo rar-y - Google Patents

Uso de pelo menos um ligante que é selecionado entre um ligante agonista que é especifico para receptores do tipo rar-a e um ligante antagonista que é especifico para receptores do tipo rar-y

Info

Publication number
BR9611035A
BR9611035A BR9611035A BR9611035A BR9611035A BR 9611035 A BR9611035 A BR 9611035A BR 9611035 A BR9611035 A BR 9611035A BR 9611035 A BR9611035 A BR 9611035A BR 9611035 A BR9611035 A BR 9611035A
Authority
BR
Brazil
Prior art keywords
ligand
specific
rar
type receptors
pct
Prior art date
Application number
BR9611035A
Other languages
English (en)
Inventor
Laszio Fesus
Zsuzsa Szondy
Uwe Reichert
Original Assignee
Cird Galderma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cird Galderma filed Critical Cird Galderma
Publication of BR9611035A publication Critical patent/BR9611035A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Psychology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Gastroenterology & Hepatology (AREA)
BR9611035A 1995-10-11 1996-10-08 Uso de pelo menos um ligante que é selecionado entre um ligante agonista que é especifico para receptores do tipo rar-a e um ligante antagonista que é especifico para receptores do tipo rar-y BR9611035A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9511946A FR2739777B1 (fr) 1995-10-11 1995-10-11 Ligand antagoniste rar-gamma ou agoniste rar-alpha en tant qu'inhibiteur d'apoptose
PCT/FR1996/001569 WO1997013506A1 (fr) 1995-10-11 1996-10-08 LIGANT ANTAGONISTE RAR-η OU AGONISTE RAR-α EN TANT QU'INHIBITEUR D'APOPTOSE

Publications (1)

Publication Number Publication Date
BR9611035A true BR9611035A (pt) 1999-07-06

Family

ID=9483437

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9611035A BR9611035A (pt) 1995-10-11 1996-10-08 Uso de pelo menos um ligante que é selecionado entre um ligante agonista que é especifico para receptores do tipo rar-a e um ligante antagonista que é especifico para receptores do tipo rar-y

Country Status (21)

Country Link
US (1) US6063797A (pt)
EP (1) EP0854711B1 (pt)
JP (1) JP3135267B2 (pt)
KR (1) KR100300214B1 (pt)
CN (1) CN1104896C (pt)
AT (1) ATE212226T1 (pt)
AU (1) AU695311B2 (pt)
BR (1) BR9611035A (pt)
CA (1) CA2231558C (pt)
DE (1) DE69618802T2 (pt)
DK (1) DK0854711T3 (pt)
ES (1) ES2172680T3 (pt)
FR (1) FR2739777B1 (pt)
HU (1) HUP9900037A3 (pt)
NO (1) NO981652L (pt)
NZ (1) NZ319647A (pt)
PL (1) PL186821B1 (pt)
PT (1) PT854711E (pt)
RU (1) RU2191008C2 (pt)
TR (1) TR199800644T2 (pt)
WO (1) WO1997013506A1 (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10158192A (ja) 1996-10-03 1998-06-16 Eisai Co Ltd 移植片対宿主疾患（ｇｖｈｄ）の治療および臓器移植時の移植片拒絶反応抑制のための医薬組成物
FR2776511B1 (fr) * 1998-03-31 2001-05-11 Galderma Rech Dermatologique Utilisation dans ou pour la preparation d'une composition d'au moins un inhibiteur de l'activite de l'acide retinoique
JP2003523166A (ja) * 1998-09-29 2003-08-05 ガミダ セル リミテッド 幹細胞および前駆細胞の増殖と分化を制御する方法
US6242473B1 (en) * 1999-01-08 2001-06-05 Maxim Pharmaceuticals, Inc. Treatment and prevention of reactive oxygen metabolite-mediated cellular damage
WO2002022113A2 (en) * 2000-09-13 2002-03-21 Bristol-Myers Squibb Company Retinoic acid receptor antagonists as promoters of angiogenesis
IL152904A0 (en) * 2002-01-24 2003-06-24 Gamida Cell Ltd Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations
WO2003062404A1 (en) * 2002-01-25 2003-07-31 Gamida-Cell Ltd. Methods of expanding stem and progenitor cells and expanded cell populations obtained thereby
WO2006030442A2 (en) * 2004-09-16 2006-03-23 Gamida-Cell Ltd. Methods of ex vivo progenitor and stem cell expansion by co-culture with mesenchymal cells
AU2005316561A1 (en) * 2004-12-17 2006-06-22 Wyeth The uses of estrogen beta agonists to treat cognitive diseases
KR100798853B1 (ko) * 2005-02-15 2008-01-28 (주)한국스티펠 레티노이드를 유효성분으로 하는 백반증 예방 및 치료용 약학적 조성물
US8846393B2 (en) 2005-11-29 2014-09-30 Gamida-Cell Ltd. Methods of improving stem cell homing and engraftment
US8082730B2 (en) * 2008-05-20 2011-12-27 Caterpillar Inc. Engine system having particulate reduction device and method
GB0915196D0 (en) 2009-09-01 2009-10-07 King S College London Therapeutic compounds and their use
EP4066826B1 (en) * 2010-09-01 2024-03-06 Thomas Jefferson University Retinoic acid receptor gamma agonists for muscle repair and regeneration
CA2863795A1 (en) 2012-02-13 2013-08-22 Gamida-Cell Ltd. Culturing of mesenchymal stem cells
US9175266B2 (en) 2012-07-23 2015-11-03 Gamida Cell Ltd. Enhancement of natural killer (NK) cell proliferation and activity
US9567569B2 (en) 2012-07-23 2017-02-14 Gamida Cell Ltd. Methods of culturing and expanding mesenchymal stem cells
WO2014199905A1 (en) * 2013-06-10 2014-12-18 Research Foundation Itsuu Laboratory Medicament for treatment of alzheimer's disease
WO2016144976A1 (en) * 2015-03-09 2016-09-15 Kings College London Combination therapy with rar alpha agonists for enhancing th1 response
KR20170132248A (ko) 2015-03-31 2017-12-01 사이로스 파마수티컬스, 인크. 레티노산 수용체-α 효능제를 이용한 치료에 대해 환자를 계층화하는 방법
EP3440046A1 (en) * 2016-04-07 2019-02-13 High Force Research Limited Synthetic retinoids for use in rar mediated conditions
US9868994B2 (en) 2016-04-08 2018-01-16 Syros Pharmaceuticals, Inc. Methods of stratifying patients for treatment with retinoic acid receptor-α agonists
CA3020173A1 (en) 2016-04-08 2017-10-12 Syros Pharmaceuticals, Inc. Rara agonists for the treatment of aml and mds

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780676A (en) * 1992-04-22 1998-07-14 Ligand Pharmaceuticals Incorporated Compounds having selective activity for Retinoid X Receptors, and means for modulation of processes mediated by Retinoid X Receptors
US5399586A (en) * 1993-03-11 1995-03-21 Allergan, Inc. Treatment of mammals afflicted with tumors with compounds having RXR retinoid receptor agonist activity
FR2713640B1 (fr) * 1993-12-15 1996-01-05 Cird Galderma Nouveaux composés aromatiques polycycliques, compositions pharmaceutiques et cosmétiques les contenant et utilisations.
FR2722985B1 (fr) * 1994-07-27 1996-09-13 Cird Galderma Nouvelles compositions a base d'un melange synergetique entre au moins un ligand specifique des rxrs et au moins un ligand specifique de rar-x ou de vdr, et leurs utilisations

Also Published As

Publication number Publication date
WO1997013506A1 (fr) 1997-04-17
PL326162A1 (en) 1998-08-31
NO981652D0 (no) 1998-04-08
CA2231558A1 (fr) 1997-04-17
TR199800644T2 (xx) 1998-07-21
EP0854711B1 (fr) 2002-01-23
KR100300214B1 (ko) 2001-11-22
HUP9900037A2 (hu) 1999-04-28
DE69618802T2 (de) 2002-11-14
NO981652L (no) 1998-06-10
CA2231558C (fr) 2003-05-27
AU7221096A (en) 1997-04-30
CN1104896C (zh) 2003-04-09
FR2739777A1 (fr) 1997-04-18
PT854711E (pt) 2002-05-31
ATE212226T1 (de) 2002-02-15
PL186821B1 (pl) 2004-03-31
HUP9900037A3 (en) 1999-11-29
RU2191008C2 (ru) 2002-10-20
ES2172680T3 (es) 2002-10-01
DK0854711T3 (da) 2002-03-25
FR2739777B1 (fr) 1997-11-14
JP3135267B2 (ja) 2001-02-13
NZ319647A (en) 2000-06-23
JPH11500448A (ja) 1999-01-12
KR19990064204A (ko) 1999-07-26
DE69618802D1 (de) 2002-03-14
EP0854711A1 (fr) 1998-07-29
CN1203529A (zh) 1998-12-30
AU695311B2 (en) 1998-08-13
US6063797A (en) 2000-05-16

Similar Documents

Publication Publication Date Title
BR9611035A (pt) Uso de pelo menos um ligante que é selecionado entre um ligante agonista que é especifico para receptores do tipo rar-a e um ligante antagonista que é especifico para receptores do tipo rar-y
ES2067957T3 (es) Uso de membranas polimerizadas interfacialmente en dispositivos de liberacion.
ATE187982T1 (de) Cytokine antagoniste
NO932936L (no) Sementeringssystemer for oljebroenner
ES2190479T3 (es) Moduladores de rxr selectivos a dimeros y metodos para su uso.
MX9204335A (es) Estructura de manejo de fluidos para uso en articulos absorbentes.
ES2170778T3 (es) Placa de fijacion y tornillo para hueso.
SE8901221D0 (sv) Arrangemang foer att utfoera utsaettningsarbete
NO951660L (no) Antirotasjonsanordning for bruk med brönnverktöy
TR28355A (tr) Hidrolik cimento "BUGHOLE" (bosluk) sayisini azaltici ilave karisimlar ve bunlarin kullanimi ile ilgili yöntem.
GT200300199A (es) Indoles 2,7-sustituidos
SE9100756L (sv) Anordning vid saagdon
DK0708105T3 (da) 5-HT4-receptoragonister
GB0227655D0 (en) Use
DK0555446T3 (da) Anvendelse af antagonister eller partielle agonister ved 5-HT1a-receptoren til behandling og forebyggelse af kognitive fors
ITTO910614A1 (it) Dispositivo rilevatore per valutare le condizioni di conforto termico in un ambiente, ad esempio nell'abitacolo di un autoveicolo.
DE69316200D1 (de) Feuchtigkeitsspender
DK0566666T3 (da) Nye glucohydrolase-inhibitorer anvendelige som antidiabetiske, antivirale og antimetastatiske midler
FR2703434B1 (fr) Dispositif de protection pour bouteille de gaz.
NO843726L (no) 2,5-disubstituerte-4(3h)-pyrimidoner med histamin h2-reseptor antagonistvirkning
DE69004827D1 (de) Alpha-adrenergene Rezeptor-Antagonisten.
TR199701011A2 (xx) 1-karba-(detia)-sefalosforin t�revleri.
BR0106473A (pt) Interface para acesso direto não digitado a sites de parceiros, equipamento dotado de interface para acesso direto não digitado a sites de parceiros, método de acesso não digitado a sites de parceiros, método de viabilização de uso de microcomputadores por meio da presença de interface para acesso direto não digitado a sites de parceiros
ES1018340Y (es) Adaptador para conexion de ordenadores.
JPS5366320A (en) Information copy service system using telephone line

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]